The FDA analyzed the vaccines’ ability to induce neutralizing antibody responses in kids that were comparable to young adults, a concept known as immunobridging. Both met the agency’s success criteria.
Related posts:
Biden’s challenge: Creating enough tests and sequencing to track the virus
Moderna in talks with FDA to increase vaccine doses per vial
Covid stimulus may leave aid for sick workers behind
How the opioid epidemic is derailing Biden’s pick to fight the pandemic
Biden doubles vaccine goal for first 100 days
Senior Democrat outlines new drug pricing plan as talks drag on
Labor turmoil rocks hospitals stretched by Delta
Democrats weigh vouchers for Medicare dental benefits amid funding squeeze
Democrats pitch industry-friendly Medicaid workaround to win Manchin’s support
FDA advisers endorse Covid-19 vaccine for kids 5-11 years old
States leapfrog feds on Covid boosters for all
Novavax asks FDA to authorize its Covid shot
